Punita Grover, MD
Hematology/Oncology · Minneapolis
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Fairview Express Care · Fairview Specialty Services
Hospitals listed: Fairview Hospital University · M Health Fairview St John'S Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Grover’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A173434 · Delinquent
Licence status: Delinquent · since 2021 · expires 2023-07-31 · University of Delhi, University College of Medical Sciences and Gtb Hospital.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- M Health Fairview St John'S HospitalMaplewood, MNAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Fairview Health Services, which runs 13 hospitals in 2 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.182, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.203, Oct 2024 – Sep 2025
- M Health Fairview University of Mn Medical CenterMinneapolis, MNAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Fairview Health Services, which runs 13 hospitals in 2 statesHome of Masonic Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 7.3 (5.7 to 9.1) · 707 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (11.6 to 16.3) · 707 cases, Jan 2024 – Dec 2024Better than the national rate — Pressure ulcer rate: 0.16 (0 to 0.61) · 6,733 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.425, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.56, Oct 2024 – Sep 2025
See every measure and the patient survey for M Health Fairview St John'S Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 0 worse of 6 measures. Readmissions: 2 better, 8 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.182 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.203 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.84 (0 to 1.82) · 897 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.58 to 1.21) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.24 (137.97 to 238.51) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 88 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 57 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.4 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.3 · 401 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12 · 313 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 307 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 3,713 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,186 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 4,320 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.58 (2.46 to 6.7) · 1,113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.92 (0.44 to 3.41) · 417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.35 (0.72 to 3.98) · 479 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.31 (0.35 to 12.27) · 433 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.36 (1.83 to 8.89) · 399 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.15 to 3.1) · 257 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.38 (0 to 1.08) · 3,573 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.581 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.27 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.53 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 401 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.4 · 933 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -7.8 · 151 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.8 · 431 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -15.1 · 339 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.6 · 754 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.3 (5.3 to 10.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.3 to 14.2) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 175 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.6 · 175 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.2 to 18.5) · 87 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.6) · 211 cases | No different | Jan 2024 – Dec 2024 |
What patients said (456 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for M Health Fairview University of Mn Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.3 (5.7 to 9.1) · 707 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (11.6 to 16.3) · 707 cases | Worse | Jan 2024 – Dec 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.61) · 6,733 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.425 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.56 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.57) · 2,072 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.64 to 1.06) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.81 (161.42 to 236.2) · 247 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 66 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 190 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.1 · 181 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 177 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.5 · 2,958 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.14 to 0.51) · 7,891 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.8 (3.15 to 6.45) · 2,510 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.01 (0.8 to 3.22) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.72 (0.41 to 3.03) · 1,587 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.36 (4.84 to 11.88) · 1,468 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.34 (2.11 to 6.57) · 1,546 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.27 to 2.94) · 820 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.3 · 87 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.659 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.942 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.923 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.94 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 101 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 420 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -32.5 · 62 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -7.6 · 240 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 63.6 · 179 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 397 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 98 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.8 · 62 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.6 to 18.8) · 321 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 322 cases | No different | Jan 2024 – Dec 2024 |
What patients said (405 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$18,458
Medicare paid this office $18,458 for 50 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $5,887 | $89 |
| Long return visit (40+ min) | 28 | $4,917 | $105 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 14 | $2,223 | $23 |
| Return visit (30+ min) | 13 | $1,614 | $70 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 21 | $1,246 | $24 |
Who their Medicare patients are
50 Original Medicare patients in 2024. Average age 67 · Women 50% · Health risk score 3.14. Sicker patients than 9 in 10 peers; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 72% · Chronic kidney disease 34% · Depression 28% · Coronary heart disease 26% · Cancer 22%.
The office billed $108,205, Medicare allowed $23,491 and paid $18,458; for 317 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 50 | 317 | 67 | 3.14 | $108,205 | $18,458 |
| 2023 | 22 | 139 | 68 | 2.05 | $45,035 | $10,153 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $6,445 | $91 |
Drugs they prescribed that Part D paid
$978,078
Pharmacies billed $978,078 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 438) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
376 generic and 62 brand-name prescriptions · $978,078 in drug cost · 63 antibiotic prescriptions to 27 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rezurock | 19 | $680,142 | $35,797 |
| Posaconazole | 13 | $15,075 | $1,160 |
| Eliquis | 11 | $6,923 | $629 |
| Acyclovir | 81 | $1,588 | $20 |
| Fluconazole | 14 | $751 | $54 |
See all 11 drugs
| Rezurock | 19 | $680,142 | $35,797 |
| Posaconazole | 13 | $15,075 | $1,160 |
| Eliquis | 11 | $6,923 | $629 |
| Acyclovir | 81 | $1,588 | $20 |
| Fluconazole | 14 | $751 | $54 |
| Valacyclovir | 12 | $556 | $46 |
| Sulfamethoxazole-Trimethoprim | 35 | $420 | $12 |
| Levofloxacin | 18 | $303 | $17 |
| Pantoprazole | 19 | $121 | $6 |
| Rosuvastatin | 14 | $54 | $4 |
| Prednisone | 15 | $33 | $2 |
Year by year
| 2024 | 438 | 60 | 0% (0) | 14% | $978,078 |
| 2020 | 25 | 14 | None | None | $912 |
| 2019 | 73 | 25 | None | None | $2,968 |
| 2018 | 328 | 41 | None | None | $21,468 |
| 2017 | 466 | 77 | 5% (22) | None | $38,221 |
| 2016 | 427 | 80 | 4% (19) | None | $31,497 |
| 2015 | 35 | 12 | None | None | $6,145 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2019: 1 drug
| Tamsulosin | 11 | $77 | $7 |
2018: 10 drugs
| Lantus | 12 | $3,270 | $272 |
| Ventolin Hfa | 12 | $661 | $55 |
| Gabapentin | 18 | $568 | $32 |
| Atorvastatin | 18 | $390 | $22 |
| Omeprazole | 19 | $204 | $11 |
| Tamsulosin | 14 | $170 | $12 |
| Metformin | 18 | $135 | $8 |
| Lisinopril | 16 | $119 | $7 |
| Amlodipine Besylate | 25 | $102 | $4 |
| Carvedilol | 12 | $90 | $7 |
2017: 13 drugs
| Spiriva | 14 | $10,432 | $745 |
| Ventolin Hfa | 14 | $960 | $69 |
| Omeprazole | 17 | $297 | $17 |
| Oxycodone-Acetaminophen | 12 | $278 | $23 |
| Atorvastatin | 17 | $179 | $11 |
| Gabapentin | 11 | $159 | $14 |
| Pantoprazole | 15 | $158 | $11 |
| Lisinopril | 18 | $105 | $6 |
| Levetiracetam | 11 | $104 | $9 |
| Hydrochlorothiazide | 14 | $102 | $7 |
| Carvedilol | 24 | $90 | $4 |
| Amlodipine Besylate | 18 | $73 | $4 |
| Prednisone | 14 | $35 | $2 |
2016: 9 drugs
| Symbicort | 18 | $7,357 | $409 |
| Gabapentin | 15 | $216 | $14 |
| Potassium Chloride | 13 | $194 | $15 |
| Atorvastatin | 14 | $128 | $9 |
| Carvedilol | 25 | $127 | $5 |
| Amlodipine Besylate | 24 | $118 | $5 |
| Furosemide | 22 | $76 | $3 |
| Lisinopril | 14 | $72 | $5 |
| Losartan | 13 | $48 | $4 |
Money from drug and device companies
$127 in 2021
| 2021 | 2 | 2 | None | $127 |
| 2020 | 3 | 3 | None | $261 |
| 2019 | 1 | 1 | None | $121 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Opdivo | $111 | 1 payment
|
| Janssen Biotech | Darzalex | $16 | 1 payment
|
See all 2 published payments
| Janssen Biotech | Meals · 2021-12-20 | Darzalex | $16 |
| E.R. Squibb & Sons L.L.C. | Meals · 2021-05-04 | Opdivo | $111 |
See earlier years (2020, 2019)
2020: $261
| Celgene | Revlimid | $112 | 1 payment
|
| Seagen | None | $99 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $50 | 1 payment
|
2019: $121
| Celgene | Revlimid | $121 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Incyte Corporation · Ruxolitinib, Human Chorionic Gonadotropin (Uhcg/Egf), and Dose De-Escalated Corticosteroids for Treatment of Minnesota High-Risk Acute Gvhd (Agvhd), A Phase I/II Study · 2024 | Their institution | $96,887 |
| Incyte Corporation · Ruxolitinib, Human Chorionic Gonadotropin (Uhcg/Egf), and Dose De-Escalated Corticosteroids for Treatment of Minnesota High-Risk Acute Gvhd (Agvhd), A Phase I/II Study · 2025 | Their institution | $81,593 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184001729
- Licence
- CA A173434, MO 2015014310, OH 35.134109California A173434: Delinquent · expires 2023-07-31
- Group
- Fairview Express Care · Fairview Specialty Services
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-05-04
- NPI last updated
- 2021-07-29
- NPI record certified
- 2021-07-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 234 Goodman St, Cincinnati, OH, 45219 · 2301 Holmes St., Kansas City, MO, 64108